NCT06215521View on ClinicalTrials.gov

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Healthy
Interventions
DRUG

Pirtobrutinib

Administered orally

DRUG

Placebo

Administered orally

DRUG

Moxifloxacin

Administered orally

Trial Locations (2)

53704

Covance Clinical Research Unit 3402 Kinsman Blvd, Madison

75247

Covance Clinical Research Unit 1341 Mockingbird Lane, Dallas

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06215521 - A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants | Biotech Hunter | Biotech Hunter